amifostine anhydrous has been researched along with Xerostomia in 72 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Xerostomia: Decreased salivary flow.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the radiation dose-response relationship on salivary dysfunction and quality of life (QOL) over time in patients with lymphoma receiving radiation therapy (RT) to the head and neck (H&N)." | 2.74 | A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. ( Hickey, G; Killion, L; Martin, C; Mauch, PM; Ng, AK; Rodrigues, NA; Silver, B; Stevenson, MA, 2009) |
| " There were no reports of Grade >/=3 amifostine-related adverse events." | 2.73 | Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck. ( Christie, D; Kennedy, T; Law, A; Pellitteri, P; Wood, C; Yumen, O, 2007) |
| "As for acute xerostomia, patients with laryngeal cancer were excluded from evaluation." | 2.71 | Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? ( Fehlauer, F; Feyerabend, T; Hinke, A; Mahlmann, B; Marx, M; Richter, E; Sommer, K; Vacha, P, 2003) |
| "The treatment of head and neck cancer continues to evolve." | 2.71 | Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. ( Costello, R; Haddad, R; Posner, M; Weeks, L; Wirth, L, 2003) |
| "Xerostomia is the most prevalent late side effect of radiation for head and neck malignancies and is cited by patients as the major cause of decreased quality of life." | 2.71 | Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data. ( Chao, KS; Haughey, B; Thorstad, WL, 2003) |
| " This is the first report focusing on amifostine related adverse effects leading to discontinuation of amifostine treatment." | 2.71 | Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. ( Alberti, W; Bajrovic, A; Fehlauer, F; Mahlmann, B; Rades, D; Richter, E, 2004) |
| "Xerostomia is one of the most prevalent late side effects of radiation for head and neck malignancies, and patients cite it as the major cause of decreased quality of life." | 2.71 | Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer. ( Chao, KS; Haughey, B; Thorstad, WL, 2004) |
| "Adults with head-and-neck cancer who underwent once-daily RT for 5-7 weeks (total dose, 50-70 Gy) received either open-label amifostine (200 mg/m2 i." | 2.71 | Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Sauer, R; Strnad, V; Wasserman, TH, 2005) |
| "Organ preservation in patients with head and neck cancer can be achieved using concomitant chemoradiation protocols." | 2.70 | Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation. ( Braaksma, M; Levendag, P, 2002) |
| "A phase II trial of SC amifostine in head and neck cancer was performed in a patient population (n = 54) similar to that studied in a phase III trial of intravenous amifostine to allow comparisons of outcomes." | 2.70 | Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. ( Anné, PR, 2002) |
| "Xerostomia was graded according to WHO criteria." | 2.69 | Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Clausen, M; Henze, E; Klutmann, S; Lassmann, S; Mester, J, 1999) |
| "Xerostomia was graded according to WHO-criteria." | 2.69 | Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer. ( Bleckmann, C; Bohuslavizki, KH; Brenner, W; Buchert, R; Clausen, M; Henze, E; Klutmann, S; Kröger, S; Mester, J, 1999) |
| "Radiotherapy for head and neck cancer causes acute and chronic xerostomia and acute mucositis." | 2.69 | Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. ( Brizel, DM; Eschwege, F; Henke, M; Monnier, A; Oster, W; Rudat, V; Russell, L; Sauer, R; Strnad, V; Wasserman, TH; Zhang, J, 2000) |
| "Nearly two thirds of all patients with cancer receive radiation therapy during the course of treatment, frequently resulting in acute skin and mucosal toxicities." | 2.49 | Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia. ( Pace, MB; Radvansky, LJ; Siddiqui, A, 2013) |
| "radiotherapy plus amifostine for cancer treatment." | 2.43 | Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006) |
| "Xerostomia is a permanent and devastating sequela of head and neck irradiation, and its consequences are numerous." | 2.43 | Management of xerostomia related to radiotherapy for head and neck cancer. ( Johnstone, PA; Kahn, ST, 2005) |
| "Radiation for head and neck cancers is often curative, but high doses are used." | 2.43 | How to reduce radiation-related toxicity in patients with cancer of the head and neck. ( Chambers, MS; Garden, AS; Lewin, JS, 2006) |
| "Pilocarpine is a useful agent as a treatment of radiation-induced xerostomia in head and neck cancer patients." | 2.43 | Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. ( de Castro, G; Federico, MH, 2006) |
| "Dry mouth (xerostomia) is one of the most common complaints following radiation therapy (RT) for head and neck cancers." | 2.42 | Radiotherapy-induced salivary dysfunction. ( Hu, K; Ship, JA, 2004) |
| " Xerostomia is a side effect of radiation therapy and, if not managed properly, can disrupt the patient's quality of life and lead to other health related issues." | 2.41 | Head and neck cancer: managing xerostomia and other treatment induced side effects. ( Gosselin, TK; Pavilonis, H, 2002) |
| " In regard to the endpoint "reduction of the salivary gland excretion rate of more than 50%," the dose-response curves yielded D50-values of 34." | 1.34 | Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine. ( Debus, J; Haberkorn, U; Herfarth, KK; Hof, H; Hoffner, S; Huber, P; Karger, CP; Münter, MW; Rudat, V, 2007) |
| "Patients with well-differentiated thyroid cancer have a good prognosis but a significant chance for local recurrence." | 1.32 | Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. ( Elkins, D; Goffman, TE; Karakla, D; Mason, ME; Mendoza, A; Shaffer, B, 2004) |
| "The degree of xerostomia has been reported to depend on the radiation dose and the salivary gland volume irradiated." | 1.31 | Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. ( Chao, KS, 2002) |
| "Xerostomia has been seen in 15 patients (Grade I) and 5 patients (Grade II) after administration of amifostine." | 1.30 | Amifostine--a radioprotector in locally advanced head and neck tumors. ( Prott, FJ; Schönekäs, KG; Wagner, W, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (11.11) | 18.2507 |
| 2000's | 55 (76.39) | 29.6817 |
| 2010's | 8 (11.11) | 24.3611 |
| 2020's | 1 (1.39) | 2.80 |
| Authors | Studies |
|---|---|
| Sardellitti, L | 1 |
| Bortone, A | 1 |
| Filigheddu, E | 1 |
| Serralutzu, F | 1 |
| Milia, EP | 1 |
| Riley, P | 1 |
| Glenny, AM | 1 |
| Hua, F | 1 |
| Worthington, HV | 1 |
| Ferraiolo, DM | 1 |
| Veitz-Keenan, A | 1 |
| Lee, MG | 1 |
| Freeman, AR | 1 |
| Roos, DE | 1 |
| Milner, AD | 1 |
| Borg, MF | 1 |
| Barbosa, SCM | 1 |
| Pereira, VBM | 1 |
| Wong, DVT | 1 |
| Santana, APM | 1 |
| Lucetti, LT | 1 |
| Carvalho, LL | 1 |
| Barbosa, CRN | 1 |
| Callado, RB | 1 |
| Silva, CAA | 1 |
| Lopes, CDH | 1 |
| Brito, GAC | 1 |
| Alencar, NMN | 1 |
| Lima-Júnior, RCP | 1 |
| Radvansky, LJ | 1 |
| Pace, MB | 1 |
| Siddiqui, A | 1 |
| Rudat, V | 4 |
| Münter, M | 1 |
| Rades, D | 2 |
| Grötz, KA | 1 |
| Bajrovic, A | 2 |
| Haberkorn, U | 2 |
| Brenner, W | 3 |
| Debus, J | 2 |
| Rodrigues, NA | 1 |
| Killion, L | 1 |
| Hickey, G | 1 |
| Silver, B | 1 |
| Martin, C | 1 |
| Stevenson, MA | 1 |
| Mauch, PM | 1 |
| Ng, AK | 1 |
| Okumura, H | 1 |
| Nasu, M | 1 |
| Yosue, T | 1 |
| Haddad, R | 2 |
| Sonis, S | 1 |
| Posner, M | 2 |
| Wirth, L | 2 |
| Costello, R | 2 |
| Braschayko, P | 1 |
| Allen, A | 1 |
| Mahadevan, A | 1 |
| Flynn, J | 1 |
| Burke, E | 1 |
| Li, Y | 1 |
| Tishler, RB | 1 |
| Koukourakis, MI | 1 |
| Tsoutsou, PG | 1 |
| Karpouzis, A | 1 |
| Tsiarkatsi, M | 1 |
| Karapantzos, I | 1 |
| Daniilidis, V | 1 |
| Kouskoukis, C | 1 |
| Ma, C | 1 |
| Xie, J | 1 |
| Chen, Q | 1 |
| Wang, G | 1 |
| Zuo, S | 1 |
| Liu, CC | 1 |
| Xia, R | 1 |
| Guadagnolo, A | 1 |
| Cormier, JN | 1 |
| Du, XL | 1 |
| Ma, DY | 1 |
| Qiu, WL | 1 |
| Zhang, CP | 1 |
| Werner-Wasik, M | 1 |
| Gosselin, TK | 1 |
| Pavilonis, H | 1 |
| Sagowski, C | 1 |
| Wenzel, S | 1 |
| Metternich, FU | 1 |
| Kehrl, W | 1 |
| Bardet, E | 1 |
| Martin, L | 1 |
| Calais, G | 1 |
| Tuchais, C | 1 |
| Bourhis, J | 2 |
| Rhein, B | 1 |
| Feham, N | 1 |
| Alphonsi, M | 1 |
| Rosine, D | 1 |
| Braaksma, M | 1 |
| Levendag, P | 1 |
| Anné, PR | 3 |
| Vacha, P | 2 |
| Fehlauer, F | 2 |
| Mahlmann, B | 2 |
| Marx, M | 2 |
| Hinke, A | 1 |
| Sommer, K | 1 |
| Richter, E | 3 |
| Feyerabend, T | 2 |
| Cassatt, DR | 1 |
| Fazenbaker, CA | 1 |
| Kifle, G | 1 |
| Bachy, CM | 1 |
| Schuchter, L | 1 |
| Meropol, NJ | 1 |
| Winer, EP | 1 |
| Hensley, ML | 1 |
| Somerfield, MR | 1 |
| Hu, K | 2 |
| Ship, JA | 3 |
| Harrison, LB | 1 |
| Weeks, L | 1 |
| Thorstad, WL | 2 |
| Haughey, B | 2 |
| Chao, KS | 3 |
| Boehme, S | 1 |
| Wilson, DB | 1 |
| Alberti, W | 1 |
| Mendoza, A | 1 |
| Shaffer, B | 1 |
| Karakla, D | 1 |
| Mason, ME | 1 |
| Elkins, D | 1 |
| Goffman, TE | 1 |
| Astudillo, L | 1 |
| Maachi, B | 1 |
| Benyoucef, A | 1 |
| Game, X | 1 |
| Rives, M | 1 |
| Bachaud, JM | 1 |
| Rosenthal, DI | 2 |
| Chambers, MS | 2 |
| Weber, RS | 1 |
| Eisbruch, A | 1 |
| Sasse, AD | 1 |
| Clark, LG | 1 |
| Sasse, EC | 1 |
| Clark, OA | 1 |
| Buentzel, J | 1 |
| Micke, O | 1 |
| Adamietz, IA | 1 |
| Monnier, A | 3 |
| Glatzel, M | 3 |
| de Vries, A | 1 |
| Wasserman, TH | 2 |
| Brizel, DM | 4 |
| Henke, M | 3 |
| Eschwege, F | 2 |
| Sauer, R | 5 |
| Strnad, V | 5 |
| Norales, G | 1 |
| Maria, V | 1 |
| de Guzman, A | 1 |
| Leonard, R | 1 |
| Aref, A | 1 |
| Kahn, ST | 1 |
| Johnstone, PA | 1 |
| Garden, AS | 1 |
| Lewin, JS | 1 |
| de Castro, G | 1 |
| Federico, MH | 1 |
| Jellema, AP | 1 |
| Slotman, BJ | 1 |
| Muller, MJ | 1 |
| Leemans, CR | 1 |
| Smeele, LE | 1 |
| Hoekman, K | 1 |
| Aaronson, NK | 1 |
| Langendijk, JA | 1 |
| Machtay, M | 1 |
| Morrison, WH | 1 |
| Irwin, DH | 1 |
| Chougule, PB | 1 |
| Estopinal, NC | 1 |
| Berson, A | 1 |
| Curran, WJ | 2 |
| Münter, MW | 1 |
| Hoffner, S | 1 |
| Hof, H | 1 |
| Herfarth, KK | 1 |
| Huber, P | 1 |
| Karger, CP | 1 |
| Shiboski, CH | 1 |
| Hodgson, TA | 1 |
| Schiødt, M | 1 |
| Kouvaris, JR | 1 |
| Kouloulias, VE | 1 |
| Vlahos, LJ | 1 |
| Samuels, MA | 1 |
| Law, A | 1 |
| Kennedy, T | 1 |
| Pellitteri, P | 1 |
| Wood, C | 1 |
| Christie, D | 1 |
| Yumen, O | 1 |
| Messerschmidt, GL | 1 |
| Oleka, N | 1 |
| Bohuslavizki, KH | 2 |
| Klutmann, S | 2 |
| Bleckmann, C | 2 |
| Lassmann, S | 1 |
| Mester, J | 2 |
| Henze, E | 2 |
| Clausen, M | 2 |
| Taylor, SE | 1 |
| Miller, EG | 1 |
| Kröger, S | 1 |
| Buchert, R | 1 |
| Schultze, J | 1 |
| Kimmig, B | 1 |
| Engel, A | 1 |
| Schönekäs, KG | 1 |
| Wagner, W | 1 |
| Prott, FJ | 1 |
| Büntzel, J | 2 |
| Schuth, J | 1 |
| Weinaug, R | 2 |
| Küttner, K | 2 |
| Fröhlich, D | 2 |
| Batcha, M | 1 |
| Zhang, J | 2 |
| Russell, L | 1 |
| Oster, W | 2 |
| Lindegaard, JC | 1 |
| Grau, C | 1 |
| Wasserman, T | 1 |
| Mackowiak, JI | 1 |
| Peeples, PJ | 1 |
| Meyer, J | 1 |
| Momm, F | 1 |
| Bendel, M | 1 |
| Grötz, K | 1 |
| Schulte, A | 1 |
| Vikram, B | 1 |
| Noël, G | 1 |
| Mazeron, JJ | 1 |
| Antonadou, D | 1 |
| Pepelassi, M | 1 |
| Synodinou, M | 1 |
| Puglisi, M | 1 |
| Throuvalas, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck[NCT00095927] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| A Randomized Phase III Study Comparing Intravenous Versus Subcutaneous Administration of Amifostine in Prevention of Xerostomia for Patients Receiving Radiotherapy for Head and Neck Carcinomas[NCT00158691] | Phase 3 | 296 participants | Interventional | 2001-03-31 | Completed | ||
| "Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"[NCT03541772] | Phase 2 | 60 participants (Actual) | Interventional | 2015-01-20 | Completed | ||
| Normal Tissue Oxygenation Following Radiotherapy[NCT00677040] | 20 participants (Actual) | Observational | 2008-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Transcutaneous oxygen detector is used to measure the partial pressure of oxygen. The unit detects electrolytes ionized by oxygen. The measuring electrode also heats the skin being measured to facilitate maximal bloodflow to the area. (NCT00677040)
Timeframe: One visit for 20 minutes
| Intervention | mmHg (Mean) |
|---|---|
| Subjects | 62.5 |
(NCT00677040)
Timeframe: One visit
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| late subcutaneous toxicitiy score 1 | late subcutaneous toxcity score 2 | late skin toxicity score 1 | late skin toxicity score 2 | |
| Subjects | 19 | 1 | 19 | 1 |
20 reviews available for amifostine anhydrous and Xerostomia
| Article | Year |
|---|---|
Xerostomia: From Pharmacological Treatments to Traditional Medicine-An Overview on the Possible Clinical Management and Prevention Using Systemic Approaches.
Topics: Amifostine; Antioxidants; Humans; Medicine, Traditional; Radiation-Protective Agents; Xerostomia | 2023 |
Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
Topics: Amifostine; Drugs, Chinese Herbal; Female; Fibroblast Growth Factor 7; Humans; Male; Pilocarpine; Qu | 2017 |
Prevention and management of radiation-induced dermatitis, mucositis, and xerostomia.
Topics: Administration, Topical; Amifostine; Analgesics; Antineoplastic Protocols; Combined Modality Therapy | 2013 |
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Amifostine; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Radiatio | 2009 |
[Current status of prevention and management of radiation-induced xerostomia].
Topics: Amifostine; Animals; Head and Neck Neoplasms; Humans; Oral Health; Radiation Injuries; Radiation-Pro | 2010 |
Clinical applications of radioprotectors.
Topics: Amifostine; Animals; Anticarcinogenic Agents; Drug Delivery Systems; Humans; Mucous Membrane; Radiat | 2001 |
Head and neck cancer: managing xerostomia and other treatment induced side effects.
Topics: Amifostine; Fatigue; Head and Neck Neoplasms; Humans; Pain; Pain Management; Skin Abnormalities; Tre | 2002 |
Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoprotection; Drug Evaluation, Pre | 2002 |
Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Topics: Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Intraoperative Period; Postop | 2003 |
Amifostine-induced fever: case report and review of the literature.
Topics: Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Fever; Head and Neck Neoplasms; Hum | 2004 |
Radiotherapy-induced salivary dysfunction.
Topics: Amifostine; Combined Modality Therapy; Head and Neck Neoplasms; Humans; Intraoperative Period; Radia | 2004 |
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad | 2006 |
Management of xerostomia related to radiotherapy for head and neck cancer.
Topics: Acupuncture Therapy; Amifostine; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Muscarin | 2005 |
How to reduce radiation-related toxicity in patients with cancer of the head and neck.
Topics: Amifostine; Anti-Infective Agents; Deglutition Disorders; Fibrosis; Free Radical Scavengers; Growth | 2006 |
Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients.
Topics: Amifostine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cytoplasmic Granules; Free Radical S | 2006 |
Management of salivary hypofunction during and after radiotherapy.
Topics: Amifostine; Dental Caries; Humans; Muscarinic Agonists; Pilocarpine; Radiation Injuries; Radiation-P | 2007 |
Amifostine: the first selective-target and broad-spectrum radioprotector.
Topics: Amifostine; Humans; Mucositis; Neoplasms; Radiation-Protective Agents; Radiotherapy; Treatment Outco | 2007 |
Preemptive pharmacologic intervention in radiation-induced salivary dysfunction.
Topics: Adrenergic beta-Agonists; Amifostine; Animals; Head and Neck Neoplasms; Humans; Iatrogenic Disease; | 1999 |
Has the outlook improved for amifostine as a clinical radioprotector?
Topics: Amifostine; Animals; Clinical Trials as Topic; Disease Models, Animal; Dogs; Dose-Response Relations | 2000 |
Radioprotection of head and neck tissue by amifostine.
Topics: Amifostine; Animals; Clinical Trials as Topic; Head and Neck Neoplasms; Humans; Mouth Mucosa; Radiat | 2002 |
27 trials available for amifostine anhydrous and Xerostomia
| Article | Year |
|---|---|
Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Double-Blind Method; Female; Head and Neck Neoplasms; Hu | 2019 |
A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2009 |
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2009 |
Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Topics: Amifostine; Carcinoma, Squamous Cell; Cytoprotection; Female; Head and Neck Neoplasms; Humans; Injec | 2002 |
Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Cytoprotecti | 2002 |
Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Topics: Adult; Aged; Amifostine; Cytoprotection; Dose Fractionation, Radiation; Female; Head and Neck Neopla | 2002 |
Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Female; Head and Neck Neo | 2003 |
Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; C | 2003 |
Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Pil | 2003 |
Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2004 |
Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Combined Modality Therapy; Head and Neck Neoplasms; Hum | 2004 |
A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Topics: Amifostine; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Parotid Gland; Radiation-Prot | 2004 |
Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Disease Prog | 2006 |
Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
Topics: Adult; Amifostine; Carcinoma, Squamous Cell; Chronic Disease; Female; Follow-Up Studies; Head and Ne | 2005 |
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Head and Ne | 2006 |
A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
Topics: Adult; Aged; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Inciden | 2007 |
Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squ | 2007 |
Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Papillary; Drug Evaluation; Female; Humans; Iodine Radioisotopes | 1999 |
Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Amifostine; Carcinoma, Papillary; Double | 1999 |
[Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, | 1999 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Adult; Aged; Amifostine; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Mi | 2000 |
Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer.
Topics: Activities of Daily Living; Adult; Aged; Amifostine; Combined Modality Therapy; Data Interpretation, | 2000 |
Protective effect of amifostine on dental health after radiotherapy of the head and neck.
Topics: Adult; Aged; Amifostine; Dental Caries; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; | 2000 |
Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Th | 2002 |
Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Carboplatin; Carcinoma, Squamous Cell; Combi | 2002 |
A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Topics: Acute Disease; Amifostine; Head and Neck Neoplasms; Humans; Injections, Subcutaneous; Nausea; Radiat | 2002 |
25 other studies available for amifostine anhydrous and Xerostomia
| Article | Year |
|---|---|
Insufficient evidence for interventions to prevent dry mouth and salivary gland dysfunction post head and neck radiotherapy.
Topics: Amifostine; Caribbean Region; Quality of Life; Salivary Glands; United States; Xerostomia | 2018 |
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation.
Topics: Amifostine; Animals; Cricetinae; Disease Models, Animal; Fluorouracil; Inflammation; Male; Protectiv | 2019 |
The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Female; Head and Neck Neoplasms; Humans; Mal | 2008 |
Effects of amifostine administration prior to irradiation to the submandibular gland in mice: autoradiographic study using 3H-leucine.
Topics: Amifostine; Animals; Autoradiography; Leucine; Male; Mice; Mice, Inbred BALB C; Radiation Injuries; | 2009 |
Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer.
Topics: Aged; Aged, 80 and over; Amifostine; Combined Modality Therapy; Female; Head and Neck Neoplasms; Hum | 2011 |
Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects.
Topics: Acute Disease; Amifostine; Animals; Drug-Related Side Effects and Adverse Reactions; Male; Radiation | 2003 |
Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
Topics: Amifostine; Animals; Female; Injections, Intravenous; Injections, Subcutaneous; Mercaptoethylamines; | 2003 |
Amifostine and chemoradiation therapy: ASCO responds.
Topics: Amifostine; Combined Modality Therapy; Humans; Mouth Mucosa; Practice Guidelines as Topic; Radiother | 2003 |
Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; Chronic Disease; Fatigue; Fem | 2004 |
Stevens-Johnson syndrome after amifostine during radiotherapy.
Topics: Amifostine; Carcinoma; Humans; Injections, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Rad | 2004 |
Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients.
Topics: Amifostine; Clinical Trials, Phase III as Topic; Head and Neck Neoplasms; Humans; Radiation-Protecti | 2004 |
Amifostine-induced back pain: a case report.
Topics: Amifostine; Back Pain; Carboplatin; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Radiation-P | 2006 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radi | 2006 |
Chemoradiotherapy for head and neck cancer: 'local' side effects are actually systemic.
Topics: Amifostine; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deglutition Di | 2006 |
Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Topics: Adult; Aged; Amifostine; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Hum | 2007 |
In regards to Münter et Al. (Int J Radiat Oncol Biol Phys 2007;67:651-659).
Topics: Adult; Aged; Amifostine; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Parotid Gland; | 2007 |
In regard to Münter et Al. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and withou
Topics: Amifostine; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Parotid Gland; R | 2007 |
[New data on cytoprotection in radiotherapy].
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Cytoprotection; Double-Bl | 1999 |
[Outcome of primary combined radio-chemotherapy in head and neck tumors with simultaneous salivary gland protection by amifostine].
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Head and Neck Neoplasms; | 1999 |
Amifostine--a radioprotector in locally advanced head and neck tumors.
Topics: Adult; Aged; Amifostine; Deglutition Disorders; Female; Head and Neck Neoplasms; Humans; Male; Middl | 1999 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |
The use of amifostine to prevent xerostomia in patients receiving radiation therapy.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Radiation-Protective Agents; Radiotherapy; Xerostomia | 2000 |
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Topics: Amifostine; Head and Neck Neoplasms; Humans; Radiation-Protective Agents; Randomized Controlled Tria | 2001 |
[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
Topics: Amifostine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glutamine; Gran | 2001 |
Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
Topics: Amifostine; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Parotid Gland; R | 2002 |